BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales

Published 06/08/2025, 19:40
BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales

Investing.com - TD Cowen has maintained its Buy rating and $60.00 price target on BridgeBio Pharma (NASDAQ:BBIO) following the company’s strong performance in Attruby sales. The stock has shown remarkable momentum, gaining nearly 98% over the past year and 50% in the last six months. According to InvestingPro data, analysts maintain a strong bullish consensus with price targets ranging from $41 to $95.

The firm noted that Attruby sales doubled in the second full quarter of availability, with the rate of new prescriptions per week showing acceleration.

TD Cowen estimates that gross-to-net discounts increased from 25% to over 35%, while free drug programs expanded from 45% to between 70-80%, which the firm considers an indicator of first-line usage.

The research firm also observed some patient assistance program utilization, with these metrics now stabilizing across the board.

TD Cowen projects that the increase in free drug patients quarter-over-quarter will drive sales growth, adding that the drug with the best point estimates and lowest price will ultimately prevail as insurance companies manage this $10-20 billion drug category over time.

In other recent news, BridgeBio Pharma reported its second-quarter 2025 earnings, revealing a notable revenue increase to $110.6 million, which exceeded the forecast of $99.72 million by 10.87%. Despite this revenue surge, the company’s earnings per share fell short of expectations, posting a loss of $0.95 against the anticipated loss of $0.75. Additionally, BridgeBio’s second-quarter Attruby sales reached $71.5 million, surpassing both Oppenheimer’s estimate of $71 million and consensus expectations of $65 million. Following these developments, Oppenheimer raised its price target for BridgeBio Pharma to $61 from $60, while maintaining an Outperform rating on the stock. These recent developments highlight a mixed financial performance for BridgeBio Pharma, with strong revenue figures but disappointing earnings results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.